Compare IDE & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IDE | MSLE |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | Canada |
| Employees | N/A | 21 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.0M | 186.9M |
| IPO Year | N/A | 2007 |
| Metric | IDE | MSLE |
|---|---|---|
| Price | $12.10 | $8.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 50.2K | 28.2K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.36 | $5.44 |
| 52 Week High | $14.30 | $13.39 |
| Indicator | IDE | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 23.36 | 38.89 |
| Support Level | N/A | $8.11 |
| Resistance Level | $13.95 | $8.59 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 1.32 | 2.80 |
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.